UY36046A - Formulaciones farmacéuticas, procesos para la preparación y métodos de uso - Google Patents
Formulaciones farmacéuticas, procesos para la preparación y métodos de usoInfo
- Publication number
- UY36046A UY36046A UY0001036046A UY36046A UY36046A UY 36046 A UY36046 A UY 36046A UY 0001036046 A UY0001036046 A UY 0001036046A UY 36046 A UY36046 A UY 36046A UY 36046 A UY36046 A UY 36046A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- pharmaceutical formulations
- preparation processes
- pharmaceutical composition
- relates
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY0001036046A UY36046A (es) | 2014-03-26 | 2015-03-25 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| CA2943808A CA2943808C (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use |
| EA201691918A EA031190B1 (ru) | 2014-03-26 | 2015-03-26 | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения |
| PE2017000171A PE20170773A1 (es) | 2014-03-26 | 2015-03-26 | Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso |
| EP15716288.4A EP3122334B1 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use |
| PCT/US2015/022792 WO2015148828A1 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use |
| GEAP201514304A GEP20186932B (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of pan-raf kinase inhibitor, processes for their preparation, and methods of use |
| CR20160483A CR20160483A (es) | 2014-03-26 | 2015-03-26 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| CN201580026318.XA CN106456787B (zh) | 2014-03-26 | 2015-03-26 | Pan-raf激酶抑制剂的医药调配物、其制备方法以及使用方法 |
| JP2016558714A JP6571105B2 (ja) | 2014-03-26 | 2015-03-26 | 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法 |
| US15/128,714 US10426782B2 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
| BR112016022219-9A BR112016022219B1 (pt) | 2014-03-26 | 2015-03-26 | Composição farmacêutica e processo de preparação da mesma |
| ES15716288T ES2744298T3 (es) | 2014-03-26 | 2015-03-26 | Formulaciones farmacéuticas de un inhibidor de cinasa pan-RAF, procesos para su preparación, y métodos de uso |
| MA039765A MA39765A (fr) | 2014-03-26 | 2015-03-26 | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation |
| DO2016000254A DOP2016000254A (es) | 2014-03-26 | 2016-09-23 | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. |
| CONC2016/0003340A CO2016003340A2 (es) | 2014-03-26 | 2016-10-24 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| ECIEPI201684317A ECSP16084317A (es) | 2014-03-26 | 2016-10-26 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970595P | 2014-03-26 | 2014-03-26 | |
| US201462048527P | 2014-09-10 | 2014-09-10 | |
| UY0001036046A UY36046A (es) | 2014-03-26 | 2015-03-25 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| PK16215 | 2015-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36046A true UY36046A (es) | 2015-10-30 |
Family
ID=57215543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036046A UY36046A (es) | 2014-03-26 | 2015-03-25 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10426782B2 (OSRAM) |
| EP (1) | EP3122334B1 (OSRAM) |
| JP (1) | JP6571105B2 (OSRAM) |
| CN (1) | CN106456787B (OSRAM) |
| BR (1) | BR112016022219B1 (OSRAM) |
| CA (1) | CA2943808C (OSRAM) |
| CO (1) | CO2016003340A2 (OSRAM) |
| CR (1) | CR20160483A (OSRAM) |
| DO (1) | DOP2016000254A (OSRAM) |
| EA (1) | EA031190B1 (OSRAM) |
| EC (1) | ECSP16084317A (OSRAM) |
| ES (1) | ES2744298T3 (OSRAM) |
| GE (1) | GEP20186932B (OSRAM) |
| MA (1) | MA39765A (OSRAM) |
| PE (1) | PE20170773A1 (OSRAM) |
| UY (1) | UY36046A (OSRAM) |
| WO (1) | WO2015148828A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2827024T3 (es) * | 2014-12-23 | 2021-05-19 | Dot Therapeutics 1 Inc | Combinación de inhibidores de Raf y de taxanos |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4065122A4 (en) * | 2019-11-27 | 2023-12-27 | Day One Biopharmaceuticals, Inc. | Solid dispersion of pan-raf kinase inhibitor |
| AU2021376286A1 (en) * | 2020-11-06 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Raf inhibitor for treating low grade glioma |
| CN117042772A (zh) * | 2020-11-06 | 2023-11-10 | 首日生物制药公司 | 用于治疗低级别胶质瘤的raf抑制剂 |
| WO2022178244A1 (en) * | 2021-02-19 | 2022-08-25 | Day One Biopharmaceuticals, Inc. | Combination of raf inhibitor and mek inhibitor |
| WO2023049807A2 (en) * | 2021-09-22 | 2023-03-30 | Sirnaomics, Inc. | Improved methods for preparing nanoparticle compositions containing histidine-lysine copolymers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
| DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
| US20050220865A1 (en) | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| ZA200806138B (en) | 2005-12-16 | 2009-11-25 | Hanmi Pharm Ind Co Ltd | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same |
| KR100767349B1 (ko) * | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 |
| EP2079450A2 (en) | 2006-11-08 | 2009-07-22 | Novavax, INC. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| JPWO2008114859A1 (ja) * | 2007-03-22 | 2010-07-08 | アステラス製薬株式会社 | ピラゾール誘導体を含有する医薬組成物 |
| TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Ｒａｆ激酶抑制劑之化合物 |
| NZ592194A (en) | 2008-09-17 | 2013-04-26 | Mylan Inc | Reversed wet granulation process for preparing granulates and pharmaceutical products containing them |
| US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| JP2015511632A (ja) * | 2012-03-30 | 2015-04-20 | 武田薬品工業株式会社 | メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 |
-
2015
- 2015-03-25 UY UY0001036046A patent/UY36046A/es not_active Application Discontinuation
- 2015-03-26 CN CN201580026318.XA patent/CN106456787B/zh active Active
- 2015-03-26 CR CR20160483A patent/CR20160483A/es unknown
- 2015-03-26 JP JP2016558714A patent/JP6571105B2/ja active Active
- 2015-03-26 WO PCT/US2015/022792 patent/WO2015148828A1/en not_active Ceased
- 2015-03-26 CA CA2943808A patent/CA2943808C/en active Active
- 2015-03-26 US US15/128,714 patent/US10426782B2/en active Active
- 2015-03-26 EP EP15716288.4A patent/EP3122334B1/en active Active
- 2015-03-26 ES ES15716288T patent/ES2744298T3/es active Active
- 2015-03-26 BR BR112016022219-9A patent/BR112016022219B1/pt active IP Right Grant
- 2015-03-26 EA EA201691918A patent/EA031190B1/ru not_active IP Right Cessation
- 2015-03-26 PE PE2017000171A patent/PE20170773A1/es unknown
- 2015-03-26 MA MA039765A patent/MA39765A/fr unknown
- 2015-03-26 GE GEAP201514304A patent/GEP20186932B/en unknown
-
2016
- 2016-09-23 DO DO2016000254A patent/DOP2016000254A/es unknown
- 2016-10-24 CO CONC2016/0003340A patent/CO2016003340A2/es unknown
- 2016-10-26 EC ECIEPI201684317A patent/ECSP16084317A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20160483A (es) | 2017-04-27 |
| JP2017511313A (ja) | 2017-04-20 |
| CN106456787A (zh) | 2017-02-22 |
| BR112016022219B1 (pt) | 2022-09-27 |
| JP6571105B2 (ja) | 2019-09-04 |
| EP3122334B1 (en) | 2019-06-26 |
| PE20170773A1 (es) | 2017-07-04 |
| GEP20186932B (en) | 2018-12-10 |
| DOP2016000254A (es) | 2017-02-15 |
| ECSP16084317A (es) | 2018-05-31 |
| US10426782B2 (en) | 2019-10-01 |
| MA39765A (fr) | 2017-02-01 |
| CO2016003340A2 (es) | 2017-02-17 |
| CA2943808A1 (en) | 2015-10-01 |
| EP3122334A1 (en) | 2017-02-01 |
| CA2943808C (en) | 2022-08-16 |
| US20170173033A1 (en) | 2017-06-22 |
| WO2015148828A1 (en) | 2015-10-01 |
| EA031190B1 (ru) | 2018-11-30 |
| BR112016022219A2 (pt) | 2018-07-10 |
| EA201691918A1 (ru) | 2017-02-28 |
| ES2744298T3 (es) | 2020-02-24 |
| CN106456787B (zh) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| GT201700234A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| UY36339A (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| CR20160527A (es) | Derivados de carboxamida | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2019001577A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| CL2016001361A1 (es) | Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| HK1233927A1 (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| CO2018005367A2 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico | |
| EA201892095A1 (ru) | Циклические динуклеотидные соединения и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220610 |